Alendronate Sodium Tablet
Product Images NDC 50090-4692

8 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 50090-4692). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Structure)

1 (Structure)
Chemical structure of alendronate sodium trihydrate, showing the molecular arrangement including phosphate groups, hydroxyl groups, and an amino-alkyl side chain.*
FDA Label Image

Fracture (Fig1 1)

Fracture (Fig1 1)
A line chart showing the cumulative incidence percentage of hip fractures over 36 months in a three-year study comparing Alendronate Sodium and placebo in patients with radiographic vertebral fractures at baseline. The graph plots time in months on the x-axis against cumulative incidence on the y-axis, with lower incidence observed in the Alendronate Sodium group.*
FDA Label Image

Treatment (Figure1 2)

Treatment (Figure1 2)
A bar chart comparing mean percent increase in bone mineral density (BMD) relative to placebo across three bone sites (Lumbar Spine, Femoral Neck, Trochanter) between U.S. and Multinational groups. Each site shows two bars with error bars indicating standard error.*
FDA Label Image

Postmenopausal (Figure1 3)

Postmenopausal (Figure1 3)
Two line graphs showing the mean percentage change in bone mineral density (BMD) from baseline over 36 months comparing Alendronate Sodium 10 mg and placebo. The first graph represents data from a US study, the second from a multinational study, each illustrating BMD changes with time in months.*
FDA Label Image

5 (Fig 1 4)

5 (Fig 1 4)
Two bar charts showing the change in bone mineral density (BMD) from baseline in postmenopausal women over 2-year and 3-year studies. The charts compare BMD changes (mean % change ± SE) at lumbar spine, femoral neck, trochanter, and total body sites between Alendronate Sodium 5 mg/day and placebo groups.*
FDA Label Image

6 (Fig1 5)

6 (Fig1 5)
A bar chart titled 'Studies in Glucocorticoid-Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year' comparing bone mineral density (BMD) percent increase relative to placebo in lumbar spine, femoral neck, and trochanter regions between U.S. and multinational studies. The chart shows mean percentage increase with error bars for each group.*
FDA Label Image

7 (Fig 1 6)

7 (Fig 1 6)
A line graph depicting the effect on serum alkaline phosphatase over 6 months in Paget's Disease patients. The graph compares placebo, etidronate 400 mg/day, and alendronate sodium 40 mg/day from two studies (multinational and U.S.), showing percent change from baseline with sample sizes (N) noted. Time in months is on the x-axis; serum alkaline phosphatase percent change on the y-axis.*
FDA Label Image

Label Image (Lbl500904692)

Label Image (Lbl500904692)
Label for ALENDRONATE SODIUM 70 mg oral tablets by A-S Medication Solutions. The label includes dosage information, storage instructions to keep tablets at 68 to 77 degrees Fahrenheit, and packaging details indicating 1 blister containing 4 tablets. The label also displays the product NDC 50090-4692-0 and mentions the strength as 70 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.